{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "Sugar Land",
      "state": "TX",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "96446",
      "recalling_firm": "QuVa Pharma, Inc.",
      "address_1": "1075 W Park One Dr Ste 100",
      "address_2": "N/A",
      "postal_code": "77478-2576",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "U.S. Nationwide",
      "recall_number": "D-0297-2025",
      "product_description": "fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 200 mg/100 mL (2 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1259-75",
      "product_quantity": "1,765 cassettes",
      "reason_for_recall": "Lack of Assurance of Sterility",
      "recall_initiation_date": "20250306",
      "center_classification_date": "20250325",
      "report_date": "20250402",
      "code_info": "Lot, expiry:  Lot 10140303, exp 04/14/2025; Lots 10140867, 10140868, exp 04/24/2025; Lot  10140965, exp 04/28/2025"
    }
  ]
}